BDA-366

• Description:

  BDA-366 is a potent Bcl2 antagonist (Ki = 3.3 nM), binding Bcl2-BH4 domain with high affinity and selectivity. BDA-366 induces conformational change in Bcl2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses growth of lung cancer cells[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302

• Target:

  Bcl-2 Family

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bda-366.html

• Purity:

  98.42

• Solubility:

  DMSO : 20 mg/mL (ultrasonic)

• Smiles:

  O=C1C2=C(C(NC[C@H]3CO3)=CC=C2NC[C@H](O)CN(CC)CC)C(C4=CC=CC=C41)=O

• Molecular Formula:

  C24H29N3O4

• Molecular Weight:

  423.50

• Precautions:

  H302

• References & Citations:

  [1]Han B, Park D, Li R, et al. Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. Cancer Cell. 2015;27 (6) :852-863.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  Bcl-2

• CAS Number:

  [1909226-00-1]